Tech Company Financing Transactions
GeoVax Labs Funding Round
GeoVax Labs, operating out of Smyrna, secured $45 million in investment from EverGlade Consulting.
Transaction Overview
Company Name
Announced On
8/28/2024
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Undisclosed
Investors
EverGlade Consulting (Eric Jia-Sobota)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
1900 Lake Park Drive 380
Smyrna, GA 30080
USA
Smyrna, GA 30080
USA
Phone
Website
Email Address
Overview
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and therapy for advanced head and neck cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Dodd
Chief Financial Officer
Mark Reynolds
Chief Medical Officer
Kelly McKee
Chief Operating Officer
John Niles
Chief Scientific Officer
Mark Newman
VP - Bus. Development
John Sharkey
VP - General Counsel
Thomas O'Brien
VP - Operations
Erica Raiden
VP - Regulatory Affairs
Teresa Genthe
Browse more venture capital transactions:
Prev: 8/28/2024: Apricus Generation venture capital transaction
Next: 8/28/2024: Mestag Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs